One To Watch

Compass Therapeutics

Company Overview

A clinical-stage oncology biotech building a pipeline of bispecific antibodies targeting tumor angiogenesis and immune checkpoints, with lead asset tovecimig on a potential BLA trajectory following positive Phase II/III data in biliary tract cancer. Compass Therapeutics (NASDAQ: CMPX) is structured around a deliberately multi-asset strategy, pairing a near-registration program with earlier-stage checkpoint bispecifics. The April 2026 COMPANION-002 progression-free survival readout marks the company's first meaningful proof point that its bispecific antibody approach can compete in hard-to-treat solid tumors.

Headquarters and Global Presence

Compass Therapeutics is headquartered in Boston, Massachusetts, and operates primarily within the US clinical development ecosystem. Its COMPANION-002 trial is a randomized, multi-center study, reflecting a broad investigational site footprint appropriate for a pivotal oncology program.

Founding and History

Compass was founded in 2014 and has operated as a clinical-stage biotech focused on the immune-oncology space since inception. In June 2024, the company completed a $132 million financing round to advance its lead candidate into the clinic and identify additional clinical assets. The company trades on NASDAQ under the ticker CMPX and has been building out its commercial and clinical leadership infrastructure ahead of a potential first regulatory filing.

Therapy Areas and Focus

Compass is focused exclusively on oncology, with a particular emphasis on tumor types that remain underserved after first-line treatment. Biliary tract cancer — cholangiocarcinoma and gallbladder cancer — carries a poor prognosis in the second-line setting, where effective options are limited and median overall survival is measured in months. The broader pipeline spans non-small cell lung cancer, triple-negative breast cancer, and Hodgkin lymphoma, reflecting a strategy of targeting both angiogenesis-driven and checkpoint-resistant tumor environments.

Technology Platforms and Modalities

Compass is built around bispecific antibodies designed to co-block two mechanistically distinct pro-tumor pathways simultaneously with a single molecule. The DLL4 x VEGF-A format used in tovecimig inhibits both Notch-driven vascular tip cell formation and VEGF-mediated angiogenesis, which preclinical and clinical data suggest produces greater vessel normalization than VEGF blockade alone. CTX-8371 takes a different angle, co-targeting PD-1 and PD-L1 to occupy both sides of the checkpoint axis — a geometry that differs from approved anti-PD-1 monotherapy and may offer activity in partially checkpoint-refractory tumors.

Key Pipeline and Programs

Tovecimig (CTX-009) is a DLL4 x VEGF-A bispecific antibody in the Phase II/III COMPANION-002 study in second-line advanced biliary tract cancer. In April 2026, tovecimig plus paclitaxel met the key secondary endpoint of progression-free survival in this randomized trial, and the company has flagged a potential BLA submission later in 2026 — which would represent its first regulatory filing.

CTX-8371 is a PD-1 x PD-L1 bispecific antibody currently in Phase I expansion cohorts across non-small cell lung cancer, triple-negative breast cancer, and Hodgkin lymphoma. Dose-escalation and early expansion cohort data are expected to be presented at ASCO 2026, making this a near-term read on whether the dual checkpoint geometry generates differentiated clinical activity.

CTX-10726 is a PD-1 x VEGF-A bispecific antibody in Phase I, with initial data expected later in 2026. CTX-471, a CD137/4-1BB agonist, rounds out the pipeline as an earlier-stage T-cell co-stimulation program, targeting a mechanism that has attracted significant industry attention despite a historically narrow therapeutic window.

Recent Developments

In April 2026, Compass announced that tovecimig met the key secondary PFS endpoint in the randomized COMPANION-002 study, clearing the path toward a potential BLA filing later in 2026. January 2026 saw a significant leadership build-out, with Arjun Prasad joining as Chief Commercial Officer and Cynthia Sirard, MD, as Chief Medical Officer — appointments that signal preparation for a commercial transition. CTX-8371 expansion cohort data and initial CTX-10726 Phase I results are both anticipated in the second half of 2026. The company reported a net loss of $66.5 million for fiscal year 2025, with R&D spending of $56.0 million, and holds more cash than debt.

Key Personnel

Thomas Schuetz, MD, PhD serves as Chief Executive Officer and Vice Chairman of the Board, bringing a clinical and scientific background to the company's oncology-focused strategy. Cynthia Sirard, MD serves as Chief Medical Officer, appointed effective January 1, 2026, with oversight of clinical development as the company approaches its first regulatory submission. Bing Gong serves as Chief Scientific Officer following a promotion in early 2026, providing continuity of scientific leadership as the bispecific platform advances across multiple Phase I and pivotal programs.

Strategic Partnerships

Compass completed a $132 million financing round in June 2024, securing the capital base to advance tovecimig through its pivotal trial and bring additional candidates into the clinic. The company has not publicly disclosed major pharma partnership or licensing deals, suggesting it is advancing its pipeline independently toward a potential first commercial product, which may itself become a partnering catalyst post-BLA filing.

FAQ Section

Biliary tract cancer — encompassing cholangiocarcinoma and gallbladder cancer — has very limited second-line treatment options, with median survival after first-line failure typically under six months. The angiogenesis dependency of these tumors makes the DLL4 x VEGF-A bispecific mechanism mechanistically plausible, and the small, well-defined patient population offers a potentially faster path to registration than a large solid tumor indication. A positive COMPANION-002 readout positions Compass for a BLA that could establish both a commercial foothold and a proof-of-concept for the broader bispecific platform.

VEGF-A drives tumor angiogenesis through established sprouting mechanisms, but DLL4-Notch signaling controls vessel tip cell selection — the upstream switch that determines which endothelial cells lead new vessel formation. Blocking VEGF-A alone can paradoxically upregulate DLL4, leading to hypersprouting of non-functional vessels. Simultaneous inhibition of both pathways with tovecimib is designed to produce more complete vessel normalization and sustained anti-tumor vascular suppression than either target alone.

Approved PD-1 antibodies such as pembrolizumab and nivolumab block PD-1 on T cells but leave PD-L1 on tumor cells free to engage other inhibitory receptors. CTX-8371 co-occupies both PD-1 and PD-L1 simultaneously, potentially creating more complete checkpoint axis blockade with a single molecule. This dual-engagement geometry may offer activity in tumors that have developed partial resistance to conventional PD-1 blockade, though the clinical data from Phase I expansion cohorts — expected at ASCO 2026 — will be the first real test of whether that mechanistic logic translates.

Following the April 2026 confirmation that tovecimig plus paclitaxel met the key secondary PFS endpoint in the randomized COMPANION-002 trial, Compass has indicated it is targeting a BLA submission later in 2026. This would be the company's first regulatory filing, making the FDA's acceptance and review of that submission a critical near-term milestone. Overall survival data from COMPANION-002 will also be closely watched as a potential label-shaping endpoint.

The pipeline spans solid tumors and hematologic malignancies. CTX-8371 is in Phase I expansion across non-small cell lung cancer, triple-negative breast cancer, and Hodgkin lymphoma — three indications with significant checkpoint-therapy precedent. CTX-10726 adds a PD-1 x VEGF-A angle that mirrors the combination strategy increasingly validated in lung and kidney cancers by approved agents. CTX-471 targets CD137/4-1BB T-cell co-stimulation, a mechanism with high scientific rationale but a history of toxicity challenges that the field is still working to navigate.

Compass is at an inflection point: one asset potentially approaching BLA submission and two others in early Phase I data-generation mode. The company reported a net loss of $66.5 million in fiscal year 2025 on R&D spending of $56.0 million, a profile consistent with a clinical-stage biotech funding a pivotal trial and two Phase I programs concurrently. The $132 million financing completed in June 2024 provides a runway through these key milestones, and the company holds more cash than debt. Appointment of a Chief Commercial Officer in January 2026 signals active preparation for a potential first commercial launch.

Compass sits at a particularly binary moment for its lead program, with several near-term events that will determine its trajectory. Key watchpoints include:

Tovecimig BLA filing and FDA acceptance in 2026 — the primary de-risking event for the company's near-term valuation.
Overall survival data from COMPANION-002 — secondary PFS is encouraging but OS will determine the depth of any commercial label.
CTX-8371 data at ASCO 2026 — the first real clinical read on whether the PD-1 x PD-L1 bispecific geometry produces differentiated activity in NSCLC, TNBC, or Hodgkin lymphoma.
CTX-10726 Phase I initial data later in 2026 — a proof-of-concept test for the PD-1 x VEGF-A combination in a bispecific format.
Cash runway management — with $56 million in annual R&D spend and no disclosed partnership revenue, capital discipline and potential partnership deals remain a watch item.

Want to Update your Company's Profile?